NASDAQ:XCUR

Exicure Stock Forecast, Price & News

$2.31

-0.19 (-7.60 %)

(As of 01/15/2021 04:55 PM ET)

Add

Compare

Today's Range

$2.25

Now: $2.31▼

$2.54

50-Day Range

$1.77

MA: $1.91▼

$2.40

52-Week Range

$0.96

Now: $2.31▼

$3.30

Volume621,705 shs

Average Volume697,161 shs

Market Capitalization$202.35 million

P/E RatioN/A

Dividend YieldN/A

Beta2.21

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes AST-008 that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂ-based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; and XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is based in Chicago, Illinois.

Overall MarketRank^™

1.87 out of 5 stars

3.5 Analyst's Opinion

Consensus Rating
Exicure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.60, Exicure has a forecasted upside of 310.3% from its current price of $2.34.
Amount of Analyst Coverage
Exicure has only been the subject of 2 research reports in the past 90 days.

5.0 Community Rank

Outperform Votes
Exicure has received 2 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Exicure has received 0 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Exicure has received 100.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Exicure and other stocks. Vote “Outperform” if you believe XCUR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XCUR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Exicure does not currently pay a dividend.
Dividend Growth
Exicure does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exicure insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 26.70% of the stock of Exicure is held by insiders.
Percentage Held by Institutions
44.15% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Exicure are expected to decrease in the coming year, from ($0.21) to ($0.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exicure is -9.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exicure is -9.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Exicure has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:XCUR

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.exicuretx.com

Phone847 673 1700

Employees57

Debt

Debt-to-Equity RatioN/A

Current Ratio6.22

Quick Ratio6.22

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.30 million

Price / Sales155.66

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.94 per share

Price / Book2.46

Profitability

EPS (Most Recent Fiscal Year)($0.46)

Net Income$-26,300,000.00

Net Margins-127.52%

Return on Equity-24.26%

Return on Assets-19.41%

Miscellaneous

Outstanding Shares87,599,000

Market Cap$202.35 million

Next Earnings Date3/9/2021 (Estimated)

OptionableNot Optionable

$2.31

-0.19 (-7.60 %)

(As of 01/15/2021 04:55 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive XCUR News and Ratings via Email

Sign-up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter.

Exicure (NASDAQ:XCUR) Frequently Asked Questions

How has Exicure's stock been impacted by COVID-19 (Coronavirus)?

Exicure's stock was trading at $1.66 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XCUR stock has increased by 39.2% and is now trading at $2.31.
View which stocks have been most impacted by COVID-19.

Is Exicure a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exicure in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Exicure stock.
View analyst ratings for Exicure or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Exicure?

Wall Street analysts have given Exicure a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exicure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Exicure's next earnings date?

Exicure is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Exicure.

How were Exicure's earnings last quarter?

Exicure, Inc. (NASDAQ:XCUR) released its earnings results on Thursday, November, 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.01. The firm earned $2.44 million during the quarter, compared to analyst estimates of $2 million. Exicure had a negative return on equity of 24.26% and a negative net margin of 127.52%.
View Exicure's earnings history.

What price target have analysts set for XCUR?

5 analysts have issued twelve-month price targets for Exicure's stock. Their forecasts range from $6.00 to $18.00. On average, they expect Exicure's share price to reach $9.60 in the next twelve months. This suggests a possible upside of 315.6% from the stock's current price.
View analysts' price targets for Exicure or view Wall Street analyst' top-rated stocks.

Who are some of Exicure's key competitors?

Some companies that are related to Exicure include Provention Bio (PRVB), Protagonist Therapeutics (PTGX), Phibro Animal Health (PAHC), Kadmon (KDMN), Lexicon Pharmaceuticals (LXRX), Avid Bioservices (CDMO), G1 Therapeutics (GTHX), MannKind (MNKD), Gossamer Bio (GOSS), Odonate Therapeutics (ODT), VBI Vaccines (VBIV), Syros Pharmaceuticals (SYRS), Collegium Pharmaceutical (COLL), Vanda Pharmaceuticals (VNDA) and ZIOPHARM Oncology (ZIOP).
View all of XCUR's competitors.

Who are Exicure's key executives?

Exicure's management team includes the following people:

Dr. Chad A. Mirkin Ph.D., Co-Founder & Director (Age 57, Pay $165k)
Dr. David A. Giljohann, CEO, Interim Principal Financial Officer, Corp. Sec. & Director (Age 40, Pay $785.46k)
Dr. Matthias G. Schroff Ph.D., Chief Operating Officer (Age 53, Pay $476.31k)
Dr. Douglas E. Feltner, Chief Medical Officer

What is Exicure's stock symbol?

Exicure trades on the NASDAQ under the ticker symbol "XCUR."

How do I buy shares of Exicure?

Shares of XCUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Exicure's stock price today?

One share of XCUR stock can currently be purchased for approximately $2.31.

How big of a company is Exicure?

Exicure has a market capitalization of $202.35 million and generates $1.30 million in revenue each year. The company earns $-26,300,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Exicure employs 57 workers across the globe.

What is Exicure's official website?

The official website for Exicure is www.exicuretx.com.

How can I contact Exicure?

Exicure's mailing address is 2430 N. Halsted St., Chicago IL, 60614. The company can be reached via phone at 847 673 1700 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here